-
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
28 Mar 2024 11:00 GMT
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® …
-
Advancing Precision in Barrett's Esophagus and Dysplasia Diagnoses: WATS3D Study Demonstrates Exceptional Consensus Among Pathologists
07 Mar 2024 09:50 GMT
SUFFERN, N.Y., March 6, 2024 /PRNewswire/ -- CDx Diagnostics, Inc., developer of the WATS3D AI platform for the detection and surveillance of Barrett's esophagus (BE) and dysplasia, today announced the publication of "WATS3D: An …
-
How to Manage Esophageal Conditions: Expert Pearls
27 Mar 2024 15:44 GMT
This transcript has been edited for clarity.
Hello. I'm Dr David Johnson, professor of medicine and chief of gastroenterology at Eastern Virginia Medical School in Norfolk, Virginia. Welcome back to another GI Common Concerns.
I recently had the …
-
The red flag cancer symptom that can only be spotted after you've eaten
25 Mar 2024 20:50 GMT
Health experts have revealed a red flag symptom of cancer that will only be noticeable after you've eaten something. A staggering number of people will be diagnosed with cancer every year - 1,000 every single day - with one in two people affected by …
-
Antireflux surgery not better than medical therapy for reducing risk of esophageal adenocarcinoma in Barrett's esophagus
28 Sep 2023 19:21 GMT
In patients with Barrett's esophagus (BE), antireflux surgery controls reflux symptoms and heals reflux-induced esophageal mucosal inflammation. This prevents the progression of BE to adenocarcinoma. The antireflux surgery and ablative endoscopic …
-
New study shows that WATS3D increases diagnostic yield of dysplasia in Barrett's esophagus, regardless of segment length
03 Aug 2023 01:23 GMT
SUFFERN, N.Y., Aug. 2, 2023 /PRNewswire/ -- CDx Laboratories - CDx Diagnostics Inc., developer of the WATS3D AI Platform for the detection and surveillance of Barrett's esophagus (BE) and dysplasia, reported positive data in a recently …
-
Study highlights need for improved screening and surveillance for Barrett's esophagus
20 Jul 2023 19:21 GMT
A new study published in Gastroenterology aims to improve the effectiveness of screening and surveillance practices for early cancer detection in Barrett's esophagus (BE).
BE is the only identifiable precursor lesion for esophageal adenocarcinoma (EAC …
-
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
21 Mar 2024 20:30 GMT
Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy
Authors conclude that EsoGuard is a "powerful screening tool" for esophageal …
-
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
20 Mar 2024 14:03 GMT
Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia
NEW YORK, March 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (…
-
Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
15 May 2023 11:25 GMT
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare” award in the seventh …